Investor Tips New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt. Articles You May Like Defining a buyer’s market ‘is always a bit tricky,’ real estate expert says: 4 signs to monitor Brian Big Idea on Commodities Alphabet moves past early stumbles in AI to deliver positive story to investors Honeywell drops on cuts to guidance. Here’s why it may provide an opportunity Here’s why you may get a smaller pay raise next year